Overweight: Clinical Trials

32 trials for Overweight, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

32 terminated. 32 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 132Terminated 32
Phase 28Terminated 8

Follow Overweight: new trials by email Literature Review of Overweight trials Research Report on Overweight

Trials (filtered) newest first · largest first

All 32 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
LY4064912, Placebo - Overweight or Obesity, Healthy
Phase 1TerminatedEli Lilly and Company772025-08-282026-09-14
Study to Learn About How the Study Medicines Called PF-07976016 and PF-06882961 Are Taken Up by the Body, and if Either of Them Change How the Body Processes the Other Medicine in Otherwise Healthy Adults With Overweight or Obesity
PF-07976016, PF-06882961 - Overweight, Obesity
Phase 1TerminatedPfizer212025-03-132025-08-07
Diazoxide Suppression Test P&F Study
Diazoxide, 3 mg/kg per dose - Insulin Resistance, Hyperinsulinemia
Phase 1TerminatedColumbia University12024-10-232026-08-07
A Phase 1b Study to Evaluate the Safety of XEN-101
XEN-101, Placebo - Obesity
Phase 1TerminatedXeno Biosciences332024-05-242024-09-24
A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570
ZP7570, Placebo - Safety and Tolerability
Phase 1TerminatedZealand Pharma842023-09-152025-04-25
A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
ALN-KHK, Placebo - Type 2 Diabetes Mellitus (T2DM)
Phase 1 / Phase 2TerminatedAlnylam Pharmaceuticals492023-03-102025-05-07
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
PF-07081532, Semaglutide - Obesity
Phase 1TerminatedPfizer322023-01-192025-01-14
ALY688-SR in Generally Healthy Overweight or Obese Adults
ALY688-SR - Overweight and Obesity
Phase 1TerminatedAllysta Pharmaceutical82021-05-192021-08-30
Investigating Effects of BOTOX on Weight Loss and Glucose Tolerance in Obese, Type 2 Diabetic Subjects
Botox 200 UNT Injection - Obese, Diabetes Mellitus, Type 2
Phase 1 / Phase 2TerminatedVanderbilt University Medical Center42021-04-292023-02-28
Single and Multiple Ascending Dose Study of AMG 171 in Subjects With Obesity
AMG 171, Placebo - Obesity
Phase 1TerminatedAmgen602019-12-132024-09-19
A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity
Semaglutide (administered by DV3396 pen), Semaglutide (administered by PDS290 pen) - Overweight, Obesity
Phase 1TerminatedNovo Nordisk A/S292019-07-152019-10-23
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
FT-4101, FT-4101 placebo, Deuterated Water - Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
Phase 1 / Phase 2TerminatedForma Therapeutics, Inc.142019-05-172025-10-20
Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study
Xenon - Obesity
Phase 1TerminatedUniversity of North Carolina, Chapel Hill172015-09-012025-11-25
Safety, Tolerability and Efficacy Study of PP1420 in HV
PP1420, Placebo - Obesity
Phase 1 / Phase 2TerminatedImperial College London492014-08-012021-09-22
Multiple Dose Study Of PF-05231023 In Obese Adult Subjects
Placebo, 100 mg PF-05231023 - Type 2 Diabetes Mellitus (T2DM)
Phase 1TerminatedPfizer42013-09-012014-09-17
Non-invasive Brain Modulation for Weight Maintenance
Brain modulation, Sham modulation - Obesity
Phase 1TerminatedMassachusetts General Hospital132013-05-012016-10-31
Study of TAP and Laparoscopic and Robotic Gynecologic Procedures and Obese Women
Ropivacaine 0.5% 20cc injectate bilaterally, Placebo - Pain
Phase 1 / Phase 2TerminatedMontefiore Medical Center352013-04-012020-08-20
Clinical Trial to Study the Safety Tolerability, Pharmacokinetics, Food Effect & Pharmacodynamics of a New Compound P7435 in Healthy, Overweight and/or Obese Subjects
P7435 - Healthy, Overweight and/or Obese Subjects
Phase 1TerminatedPiramal Enterprises Limited322012-05-012013-07-09
Peripheral Vasodilation in Obese Humans
Drug Trial 1 (EDD), Drug Trial 2 (ROV) - Obesity
Phase 1TerminatedUniversity of Wisconsin, Madison82012-04-162022-02-11
Molecular Regulation of Muscle Glucose Metabolism
U100 Humulin, Exercise - Obesity, Type 2 Diabetes Mellitus
Phase 1TerminatedMayo Clinic482012-04-012017-11-27

Showing 20 of 32. Sign in to see all of them.

Narrower conditions

Obesity (30)  ·  Diabetes Mellitus, Type 2 (7)  ·  Insulin Resistance (4)  ·  Nutrition Disorders (3)  ·  Non-alcoholic Fatty Liver Disease (2)  ·  Aneurysm (1)  ·  Body Weight (1)  ·  Diabetes Mellitus (1)  ·  Dwarfism (1)  ·  Dwarfism, Pituitary (1)  ·  Fatty Liver (1)  ·  Glucose Intolerance (1)  ·  Hyperinsulinism (1)  ·  Lipid Metabolism Disorders (1)

Broader conditions

Nutritional and Metabolic Diseases (32)  ·  Pathological Conditions, Signs and Symptoms (32)  ·  Body Weight (31)  ·  Overnutrition (31)  ·  Signs and Symptoms (31)  ·  Nutrition Disorders (29)  ·  Metabolic Diseases (10)  ·  Endocrine System Diseases (9)  ·  Glucose Metabolism Disorders (9)  ·  Diabetes Mellitus (7)  ·  Hyperinsulinism (4)  ·  Digestive System Diseases (2)  ·  Liver Diseases (2)  ·  Body Weight Changes (1)

Interventions

semaglutide (2)  ·  Anastrozole (1)  ·  Botulinum Toxins, Type A (1)  ·  Breakfast (1)  ·  Corn Oil (1)  ·  Diazoxide (1)  ·  Exercise (1)  ·  Goserelin (1)  ·  Insulin (1)  ·  Insulin, Regular, Human (1)  ·  Omacor (1)  ·  PF-05231023 (1)  ·  Ropivacaine (1)  ·  Sodium Chloride (1)  ·  Testosterone (1)

Sponsors

Novo Nordisk A/S (3)  ·  Pfizer (3)  ·  Massachusetts General Hospital (2)  ·  Allysta Pharmaceutical (1)  ·  Alnylam Pharmaceuticals (1)  ·  Amgen (1)  ·  AstraZeneca (1)  ·  Boston University (1)  ·  Columbia University (1)  ·  Eli Lilly and Company (1)  ·  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1)  ·  Forma Therapeutics, Inc. (1)  ·  GlaxoSmithKline (1)  ·  Imperial College London (1)  ·  Indiana University (1)

Countries

United States (22)  ·  United Kingdom (3)  ·  Australia (2)  ·  Germany (2)  ·  India (2)  ·  Brazil (1)  ·  Canada (1)  ·  Singapore (1)

Top investigators

Ben Snyder, MD (1)  ·  Bruno Geloneze, MD, PhD (1)  ·  Carine M Lenders, MD, MS, ScD (1)  ·  Dr Dharmesh Domadia (1)  ·  Dr Madhavi Latha Kodru (1)  ·  Frances J Hayes, MD (1)  ·  Ja Hyun Shin (1)  ·  Jack A Yanovski, M.D. (1)  ·  James Ritter, BM BCH, MRCP, FRCP (1)

Results publications

PMID 19475464, PMID 22088584, PMID 25453088, PMID 41388232, PMID 42053447

NIH funding

2014 (1), 2018 (1), K23AT004251 (1), R01HL105820 (1)